Quality of life in cutaneous t-cell lymphoma patients treated with the Anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from MAVORIC.
dc.contributor.author | Huen, A | |
dc.contributor.author | Porcu, P | |
dc.contributor.author | Hudgens, S | |
dc.contributor.author | Quaglino, P | |
dc.contributor.author | Cowan, Richard A | |
dc.contributor.author | Floden, L | |
dc.contributor.author | Tsianakas, A | |
dc.contributor.author | Leoni, M | |
dc.contributor.author | Dale, S | |
dc.contributor.author | Duvic, M | |
dc.date.accessioned | 2018-11-12T14:38:59Z | |
dc.date.available | 2018-11-12T14:38:59Z | |
dc.date.issued | 2018-09 | |
dc.identifier.citation | Quality of life in cutaneous t-cell lymphoma patients treated with the Anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from MAVORIC. 2018, 18:S289 Clin Lymphoma Myeloma Leuk | en |
dc.identifier.issn | 21522650 | |
dc.identifier.doi | 10.1016/j.clml.2018.07.228 | |
dc.identifier.uri | http://hdl.handle.net/10541/621315 | |
dc.language.iso | en | en |
dc.relation.url | https://linkinghub.elsevier.com/retrieve/pii/S2152265018309777 | en |
dc.rights | Archived with thanks to Clinical Lymphoma Myeloma and Leukemia | en |
dc.title | Quality of life in cutaneous t-cell lymphoma patients treated with the Anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from MAVORIC. | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | MD Anderson Cancer Center, Houston, Texas | en |
dc.identifier.journal | Clinical Lymphoma Myeloma and Leukemia | en |